Numan, a digital platform for men’s health in Europe, has raised £15 million in growth debt to fuel its expansion and meet growing demand.

The digital-first service provides men with treatments for erectile dysfunction, premature ejaculation, hair loss and nutritional deficiencies.

Its aim is to provide men with tools to improve health and wellbeing and confront the gender gap when it comes to healthcare-seeking behaviours.

The financing was provided by growth debt investor Kreos Capital and completes a $60.1m Series B round which was led by White Star Capital, with participation from Novator, VNV Global, and Anthemis Exponential. 

It coincides with the scaleup launching its blood testing proposition – the Fear Nothing Blood Test – in the UK as it looks to double headcount in 2022.

Targeted at men who may be neglecting their health, the campaign encourages patients to test their blood fearlessly – with the possibility of getting the test for free if all results come back within a normal range.

Since its inception, the company says it has helped hundreds of thousands of men across the UK, with the business growing organically and via two strategic acquisitions in the UK and Sweden. 

The key to commercialising a medical device

“This most recent funding round is a significant milestone on our journey to help millions of men take better care of themselves,” said CEO and founder Sokratis Papafloratos.

“We are delighted to be working with Kreos Capital alongside our wider team of brilliant investors and look forward to this next stage of accelerating Numan’s plans.

“We’re building a new model around care with the patient at its centre, and this funding enables us to invest even further in our product, technology and growth.”